These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 11745477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K.
    Int J Cancer; 2002 Mar 10; 98(2):310-5. PubMed ID: 11857424
    [Abstract] [Full Text] [Related]

  • 8. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.
    J Natl Cancer Inst; 2003 Dec 17; 95(24):1825-33. PubMed ID: 14679152
    [Abstract] [Full Text] [Related]

  • 9. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
    Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G.
    Br J Cancer; 2002 May 06; 86(9):1518-23. PubMed ID: 11986789
    [Abstract] [Full Text] [Related]

  • 10. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.
    Breast Cancer; 2004 May 06; 11(4):367-73. PubMed ID: 15604992
    [Abstract] [Full Text] [Related]

  • 11. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2004 Jan 15; 10(2):784-93. PubMed ID: 14760102
    [Abstract] [Full Text] [Related]

  • 12. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
    Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M.
    J Cancer Res Clin Oncol; 2003 Mar 15; 129(3):165-74. PubMed ID: 12712332
    [Abstract] [Full Text] [Related]

  • 13. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.
    Mol Cancer Ther; 2001 Dec 15; 1(2):85-94. PubMed ID: 12467226
    [Abstract] [Full Text] [Related]

  • 14. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA, Trinks C, Abdiu A, Thunell LK, Hallbeck AL, Walz TM.
    Melanoma Res; 2009 Jun 15; 19(3):156-66. PubMed ID: 19434003
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 15; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 16. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.
    Int J Cancer; 2002 Mar 20; 98(3):463-9. PubMed ID: 11920601
    [Abstract] [Full Text] [Related]

  • 17. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B, Chang CM, Yuan M, McKenna WG, Shu HK.
    Cancer Res; 2003 Nov 01; 63(21):7443-50. PubMed ID: 14612544
    [Abstract] [Full Text] [Related]

  • 18. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J.
    Clin Cancer Res; 2003 Apr 01; 9(4):1274-83. PubMed ID: 12684395
    [Abstract] [Full Text] [Related]

  • 19. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.
    Clin Cancer Res; 2004 Jan 15; 10(2):658-67. PubMed ID: 14760089
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR.
    Clin Cancer Res; 2004 Jul 15; 10(14):4874-84. PubMed ID: 15269164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.